Literature DB >> 29754633

Morbidity of Cushing's Syndrome and Impact of Treatment.

Susan M Webb1, Elena Valassi2.   

Abstract

Cortisol excess in Cushing's syndrome is associated with metabolic, cardiovascular, and cognitive alterations, only partially reversible after resolution of hypercortisolism. Elevated cardiovascular risk may persist after eucortisolism has been achieved. Fractures and low bone mineral density are also described in Cushing's syndrome in remission. Hypercortisolism may induce irreversible structural and functional changes in the brain, leading to neuropsychiatric disorders in the active phase of the disease, which persist. Sustained deterioration of the cardiovascular system, bone remodeling, and cognitive function along with neuropsychological impairment are associated with high morbidity and poor quality of life before and after remission.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cushing’s syndrome; Morbidity; Quality of life; Remission

Mesh:

Year:  2018        PMID: 29754633     DOI: 10.1016/j.ecl.2018.01.001

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

1.  Telomere Length Changes in Children With Cushing Disease: A Pilot Study.

Authors:  Christina Tatsi; Chelsi Flippo; Fabio R Faucz; Ninet Sinaii; Constantine A Stratakis
Journal:  J Endocr Soc       Date:  2020-06-07

Review 2.  Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease.

Authors:  Isadora P Cavalcante; Annabel Berthon; Maria C Fragoso; Martin Reincke; Constantine A Stratakis; Bruno Ragazzon; Jérôme Bertherat
Journal:  Nat Rev Endocrinol       Date:  2022-08-03       Impact factor: 47.564

3.  Spinal epidural lipomatosis: a rare and frequently unrecognized complication of Cushing syndrome.

Authors:  Noha Mukhtar; Ali S Alzahrani
Journal:  Endocrine       Date:  2022-03-08       Impact factor: 3.925

4.  Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.

Authors:  Maria Fleseriu; Stephan Petersenn; Beverly M K Biller; Pinar Kadioglu; Christophe De Block; Guy T'Sjoen; Marie-Christine Vantyghem; Libuse Tauchmanova; Judi Wojna; Michael Roughton; André Lacroix; John Newell-Price
Journal:  Clin Endocrinol (Oxf)       Date:  2019-10-01       Impact factor: 3.478

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.